Kainos Medicine, Inc.

₩1,087As of Sun 8 Nov 2026, 12:00 UTC
KOSDAQ:284620Healthcare
Country South Korea
PE (Fwd) •••
TSR 6Y CAGR (38.94%)
Div yield —
ROE (107.66%)
Biological Products, Except Diagnostic Substances
Beta (5Y) 0.89
PE TTM —
TSR TTM —
Mkt cap ₩35.56B
ROIC (60.65%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩1,273
17.13%
66.63%
Hold 9|11|6|7|1
4Q25
1Q26
2Q26
3Q26
Earnings per share₩
13.73
13.66
14.88
16.65
23.98%
12.20%
14.78%
23.33%
Revenue₩B
2.375
2.382
2.350
2.426
0.01%
1.66%
2.90%
7.89%
Peers (US$26.22M)
Cap (US$)
PE
26.04M
—
23.50M
—
Capital
TTM
5Y
10Y
Leveragex
0.688
—
—
EBIT/Intx
7.975
0.507
0.422
Own earn%
(60.62)
(193.40)
(162.77)
Sh yield%
51.70
15.46
14.70
Owners
Insiders/Inst%
12.22
56.78
Short interest%
2.66
SBC / revenue%
2.15
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
17–24
$1 testx
—
Incr. ROIC%
33